Pre-made Dilpacimab benchmark antibody ( Bispecific mAb, anti-DLL4;VEGFA therapeutic antibody, Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-145

Pre-Made Dilpacimab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-145-1mg 1mg Inquiry
GMP-Bios-ab-145-10mg 10mg Inquiry
GMP-Bios-ab-145-100mg 100mg Inquiry
GMP-Bios-ab-145-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Dilpacimab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody
INN Name Dilpacimab
TargetDLL4;VEGFA
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;1bj1:HL:KJ
99% SI StructureNone;None
95-98% SI StructureNone;6bft:HL:AB/1cz8:HL:YX
Year Proposed2018
Year Recommended2019
CompaniesAbbVie
Conditions Approvedna
Conditions ActiveColorectal cancer;Solid tumours
Conditions Discontinuedna
Development Techna